Tag: SCS

Abbott to receive multiple CES 2023 awards for neurostimulation and pacemaker...

Abbott has been recognised by the Consumer Technology Association (CTA) with three Consumer Electronics Show (CES 2023; 5–8 January, Las Vegas, USA) Innovation Awards...

Nevro announces US FDA approval of HFX iQ system to personalise...

Nevro Corporation has announced that it has received approval from the US Food and Drug Administration (FDA) for the Senza HFX iQ spinal cord stimulation (SCS)...

Onward reports positive study results in restoring arm and hand function...

Onward Medical recently announced that the Up-LIFT pivotal study evaluating its non-invasive spinal cord stimulation (SCS) ARC-EX therapy achieved its primary effectiveness endpoint of...

Nevro announces positive coverage updates for treatment of painful diabetic neuropathy...

Nevro Corporation has announced that US health plan Aetna has updated its spinal cord stimulation (SCS) coverage policy to explicitly cover painful diabetic neuropathy...

Gimer Medical granted IDE approval for spinal cord stimulation system

Gimer Medical today announced that the company’s spinal cord stimulation (SCS) system was granted conditional investigational device exemption (IDE) approval by US Food and...

Abbott gains US FDA approval for Proclaim Plus spinal cord stimulation...

Abbott has announced that the US Food and Drug Administration (FDA) has approved its new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360...

Saluda Medical presents data on 24-month holistic response to spinal cord...

Saluda Medical has announced that Steven Falowski (Argires-Marotti Neurosurgical Associates of Lancaster, Lancaster, USA) recently presented late-breaking 24-month data from the company’s EVOKE study at...

High-frequency SCS demonstrates “substantial improvement” in health-related quality of life outcomes

Nevro Corporation has announced that the complete 12-month results from the SENZA-PDN randomised controlled trial (RCT), including health-related quality of life outcomes in patients with...

High responder rates, substantial pain relief and no explants among key...

Nevro Corporation has announced the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022, New Orleans, USA) supporting the use of...

Nevro announces upcoming presentation of new SENZA-PDN clinical data

Nevro Corporation has announced that data from the SENZA painful diabetic neuropathy (PDN) randomised controlled trial (RCT)—which the company says is the largest RCT to...

INS 2022: Dorsal horn dendrite stimulation offers “true breakthrough” in pain...

A novel approach to spinal cord stimulation (SCS), which involves targeting the dorsal horn dendrite—in contrast with more traditional ‘axonal’ SCS techniques—has been labelled...

Recommended use of SCS in neuropathic pain has not led to...

Only a small proportion of neuropathic pain patients in England who are potentially eligible for spinal cord stimulation (SCS) have received this intervention over...

Saluda Medical raises US$125 million to boost Evoke spinal cord stimulation...

Saluda Medical has finalised US$125 million in equity financing, with the proceeds being used in part to operationalise and scale commercialisation of the company’s Evoke spinal...
senza-nsrbp

High-frequency SCS drives impactful outcomes for non-surgical refractory back pain patients

Following the recent introduction of key data supporting the use of high-frequency spinal cord stimulation (SCS) in the treatment of non-surgical refractory back pain...

Saluda Medical receives FDA approval for Evoke SCS system to treat...

Saluda Medical has announced that it has received full approval from the US Food and Drug Administration (FDA) for the Evoke spinal cord stimulation (SCS)...

Multiple-modality spinal cord stimulation demonstrates sustained improvement in chronic pain outcomes

A spinal cord stimulation (SCS) system capable of simultaneously delivering multiple treatment modalities has produced a sustained improvement in outcomes in a randomised controlled...

NeuroOne releases successful completion of long-term stimulation tests with novel, thin-film...

NeuroOne Medical Technologies has announced that it successfully completed initial, bench-top, long-term stimulation testing on a novel design of its thin-film electrode technology. The...

Nevro announces publication of 12-month data on high-frequency SCS for non-surgical...

Nevro Corporation has announced online publication of 12-month data from the SENZA-NSRBP randomised controlled trial (RCT) in Journal of Neurosurgery: Spine. These data show that...
senza-pdn study

NANS 2022: New 18-month data show durability of high-frequency SCS for...

This year’s North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) saw 18-month data from SENZA-PDN—a randomised controlled trial (RCT) evaluating the...

Medtronic announces FDA approval of SCS therapy for diabetic peripheral neuropathy

Medtronic has received US Food and Drug Administration (FDA) approval of its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator for the treatment of chronic...

Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...

Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...

Medtronic announces results showing meaningful pain relief using DTM SCS endurance...

Medtronic has announced three-month results from an on-label, prospective, multicentre study showing meaningful pain relief using DTM SCS endurance therapy—a modified, lower-energy variation of the...

FDA grants Breakthrough Device designation to Wavegate for StimuLux system

Wavegate Corporation has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation for its StimuLux optical reflectometry system for closed-loop...

Saluda announces sustained, long-term pain relief results with closed-loop SCS in...

Saluda Medical today announced long-term results from its double-blind, Level 1 EVOKE trial, which have been published in JAMA Neurology and demonstrate superior, sustained pain...

Boston Scientific to present new data on advances in chronic pain...

Boston Scientific has announced key data that will be featured at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA)....

Abbott announces expanded MRI compatibility for Proclaim XR spinal cord stimulation...

Abbott has announced that the US Food and Drug Administration (FDA) has approved new, expanded magnetic resonance imaging (MRI) compatibility for its Proclaim XR spinal cord...
spinal cord stimulation patient access

Current gaps and barriers in patient access to spinal cord stimulation

Maricela Schnur (St Luke’s Hospital, Duluth, USA) highlights a handful of socioeconomic disparities, racial differences, and psychological and psychiatric factors, that currently present difficulties...
scs surgical infection

Antibiotic envelopes appear safe and effective in decreasing SCS surgical site...

Antibiotic impregnated envelopes appear to be a safe and effective modality for decreasing surgical site infection risks in spinal cord stimulation (SCS) implantation, according...
nevro patent infringements

Nevro announces plans to appeal jury decision in spinal cord stimulation...

Nevro Corporation has provided an update on its position following a Delaware jury’s decision to award Boston Scientific US$20 million over patent infringements. The...

NeoSpine first to offer spinal cord stimulation for treatment of painful...

NeoSpine is now offering spinal cord stimulation (SCS) procedures for the treatment of painful diabetic neuropathy (PDN) via its HFX system—a newly approved nondrug treatment...
scs diabetic neuropathy

High-frequency SCS takes the stage to relieve chronic pain from diabetic...

Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...
crisp study scs

CRISP study indicates clinical benefit of non-paraesthesia-based approaches in burst SCS...

The CRISP (Comparison of paraesthesia mapping to anatomic midline-based burst programming strategies) study, published in Neuromodulation: Technology at the Neural Interface, has found that...

Boston Scientific launches FAST—a new therapy for spinal cord stimulation

Boston Scientific has announced the European launch of FAST—a new, fast-acting sub-perception therapy that the company says is clinically proven to demonstrate significant and...
ulf neuromodulation

Presidio Medical publishes clinical and preclinical research on ULF neuromodulation therapy

Presidio Medical has announced that research involving its novel ultra-low frequency (ULF) neuromodulation therapy has been published in Science Translational Medicine. The publication, titled...
dtm scs therapy

DTM SCS: A unique, tailored and highly effective therapy option for...

Michael Fishman (Wilmington, USA) discusses the benefits of Differential Target Multiplexed spinal cord stimulation (DTM SCS; Medtronic)—when compared to more conventional SCS therapy options—and...

Temporary SCS could represent “new paradigm” in preventing atrial fibrillation

In a randomised pilot study, temporary spinal cord stimulation (SCS) has demonstrated efficacy in the suppression of postoperative atrial fibrillation (AF) following coronary artery...

Nevro announces FDA approval of 10kHz high-frequency SCS therapy for painful...

Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system for the treatment of chronic pain associated with...
medtronic vanta

Medtronic announces FDA approval of recharge-free Vanta spinal cord stimulation implant

Medtronic has received US Food and Drug Administration (FDA) approval for Vanta—a high-performance, recharge-free implantable neurostimulator (INS) with a device life that can be...
spinal cord stimulation explant rate

Up to 13% of patients could have their spinal cord stimulator...

According to a study published in Neuromodulation, five years after implantation, spinal cord stimulators have been explanted in 13.5% of patients. Furthermore, about 10%...
burst spinal cord stimulation TRIUMPH

Burst spinal cord stimulation improves psychosocial outcomes and reduces opioid usage...

A study investigating chronic pain sufferers treated with burst spinal cord stimulation (B-SCS) has concluded that improvements were observed among all psychological measures at...

Educational curriculum for spinal cord stimulation developed to fill “unmet need”

A spinal cord stimulation (SCS) training curriculum has been developed by a multidisciplinary taskforce of the North American Neuromodulation Society’s (NANS) education committee. It...
closed-loop SCS Saluda Medical Tim Deer

Novel intermittent dosing burst spinal cord stimulation deemed safe and efficacious...

A novel intermittent dosing burst paradigm in spinal cord stimulation (SCS) has effectively relieved pain in patients with chronic intractable pain. Authors Timothy Deer,...
closed-loop SCS Saluda Medical Tim Deer

New study finds high responder rates for ECAP-controlled, closed-loop spinal cord...

A randomised, double-blind trial finds ECAP-controlled closed-loop spinal cord stimulation (SCS) statistically superior for the treatment of chronic pain, compared to open-loop stimulation. At...
saluda Medical US evoke

Saluda Medical results of US Evoke pivotal study through 12 months...

Saluda Medical has announced The Lancet Neurology journal published results from the US pivotal study demonstrating its Evoke ECAP-controlled, closed-loop spinal cord stimulation (SCS)...

Nevro announce launch of a new medical device for the treatment...

Nevro today announced it has received approval from the US Food and Drug Administration (FDA) for the Senza Omnia spinal cord stimulation (SCS) system....
proclaim abbott

FDA approves low-dose spinal cord stimulator for chronic pain

Abbott has received FDA approval for its Proclaim XR recharge-free neurostimulation system for people with chronic pain. A press release reports that the Proclaim...
saluda medical evoke

Saluda Medical announces European commercial launch of Evoke, the ECAP-controlled, closed-loop...

Saluda Medical has announced the award of CE mark and the European commercial launch of the Evoke ECAP-controlled, closed-loop spinal cord stimulation (SCS) system...
pain scores SCS trial

Low pain scores following spinal cord stimulation trials found predictive of...

Low pain scores after spinal cord stimulation (SCS) trials are predictive of successful SCS implants with high sensitivity, according to a recent study. The...
Evoke Lawrence Poree INS SCS

The clinical utility of evoked compound action potentials is echoed by...

New data from both the Evoke and Avalon studies reiterate the importance of objective neurophysiological measures and clinically meaningful outcomes. These studies evaluated the...

Nevro announces completion of patient enrolment in multicentre RCT of high...

Nevro has announced that it has completed patient enrolment in its prospective, multicentre randomised controlled trial (RCT) for the treatment of chronic pain for...

Similar success rates for anatomic and targeted lead placement for spinal...

“Anatomical lead placement is a viable alternative to targeted lead placement for spinal cord stimulation,” concluded Jason E Pope, Evolve Restorative Center, Santa Rosa,...

The first wireless spinal cord stimulator system elicits a high response...

A study evaluating different waveforms within a wireless spinal cord stimulator (SCS) device (Stimwave) has found high response rates for patients receiving both high...

Placebo-controlled RCTs of spinal cord stimulation are on the rise, but...

Important methodological aspects of clinical trials of spinal cord stimulation (SCS) using a placebo are consistently being poorly reported, says a recent systematic review....

Key findings from a review of the indications, complications, and incidence...

A retrospective database review of 12,297 spinal cord stimulator (SCS) patients outlines key findings concerning the indications, incidence of minor and major complications, and...

Abbott partners with NIH on BRAIN initiative to advance research for...

Abbott have announced that it has partnered with the National Institutes of Health (NIH) on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative...

Stimwave announces publication of 10 kHz Freedom Stimulator SURF RCT results

Stimwave has announced publication of the results of the first ever randomised, controlled trial (RCT) comparing wireless high-frequency (HF: 10 kHz) spinal cord stimulation...
Ricardo Vallejo

Novel differential-target multiplexed technique outperforms conventional SCS

Continuous differential-target multiplexed (DTM) spinal cord stimulation (SCS) provides better thermal and mechanically induced pain relief compared to high-rate and low-rate SCS, concluded Ricardo...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

Evoke: The first RCT to measure spinal cord activations in response...

The protocol design for a multicentre, prospective, randomised, double-blind study comparing ECAP- (evoked compound action potential) controlled closed-looped with open-loop, fixed output spinal cord...

Majority of radiculopathy patients prefer burst to conventional tonic stimulation

BurstDR stimulation confers a greater reduction in leg and back pain intensity on patients with failed back surgery syndrome that tonic stimulation does, a...

Nuvectra receives full-body MR-conditional CE Mark approval for Algovita

Nuvectra has announced that it has received full-body MR-conditional approval for the Company’s Algovita spinal cord stimulation (SCS) system from its European Notified Body,...

Nuvectra receives FDA head-only MR-conditional approval for Algovita

Nuvectra has announced that it has received US Food and Drug Administration (FDA) head-only MR-conditional approval for the company’s Algovita spinal cord stimulation (SCS) system. Scott...